Breast Cancer Screening What Differences

¶ … Breast Cancer Screening

What differences are there between the Case Study results and the current healthcare industry research, trends, treatment protocols, and published data results you identified?

The case study results show that overall sensitivity in women under age fifty was 78% and women with dense breast tissue had sensitivity at seventy percent for digital screenings and 51% and 55% for film screenings. Overall the sensitivity for digital screenings was at 70% and 66% for film screenings overall. According to this case only sixty-six percent of all women and fifty one percent of women under the age of fifty who have breast cancer will be identified by this screening test. The test correctly recognizes ninety percent of women under age fifty without breast cancer. With a specificity of ninety percent, ten percent of those without breast cancer will be false positives.

Today, sensitivity is just about seventy-nine percent but is lesser in younger women and in those with dense breast tissue. In general specificity is about ninety percent and is lesser in younger women and in those with dense breasts (Breast Cancer Screening Modalities, n.d.). Sensitivity for Clinical Breast Exam (CBE) has been reported to range from forty to sixty-nine percent, and its specificity ranges from eighty-eight to ninety-nine percent. Trials in which CBE is combined with mammography have established a mortality reduction of fourteen to twenty-nine percent. Like BSE, the sensitivity and value of CBE is related, in fraction, to the skill of the healthcare provider doing the examination. When CBE is done prior to mammography, it may be useful in recognizing an area of doubt that might not be readily visible on mammography or provide guidance in selecting supplementary imaging techniques (Breast Cancer Screening, 2006).

2. Are the Breast Cancer Screening patient outcomes between the Case Study data results and the current data results that you identified better or worse? Explain.

The results of current patient outcomes appear to be better than those that were reported in the case study. This is due to the fact that the mammography test has improved over the years. Mammography persists to advance and offers facilities an assortment of alternatives when conducting mammography screening and diagnostic services. One of the most basic transformations in radiology has been an alteration from screen-film to digital image attainment, and clinical investigation in recent years has centered on the corroboration of digital studies in mammography and other imaging applications. There are relative compensations and weaknesses to both screen-film and digital studies, and facilities should consider these cautiously when making the choice to keep a screen-film system or changeover to digital image acquisition (Barke, n.d.)

In addition to the superior diagnostic value in women who are under the age of fifty, those with dense breasts, and pre-menopausal women, digital mammography could present supplementary advantages. For example, digital imaging permits for streamlined, electronic image sharing and archiving capabilities. Dissimilar from screen-film images, the reader can without difficulty manipulate digital images to assist in results reading. Digital mammography also provides for enhanced visualization in people with breast implants, and enhanced contrast resolution can be realized with digital mammography in opposition to screen-film mammography. On average, digital mammography exposes people to a lower radiation dose than screen-film modalities. Even though digital mammography symbolizes a significant advance in breast imaging, screen-film mammography is still a feasible modality that is more cost effective for facilities that do not have the capital to right away transition to a digital platform. The option between screen-film and digital mammography is a significant choice for many facilities, but there are other modalities that are now being included into the typical breast cancer screening algorithm and deserve better concentration in some people at an augmented risk of developing the illness (Barke, n.d.)

3. From your research and analysis of the Breast Cancer Screening process, does the data demonstrate a favorable or unfavorable link between Breast Cancer Screening detection performed before disease symptoms have manifested in the patient, as opposed to diagnostic testing that takes place after disease symptoms have manifested in the patient?

Mammograms can be utilized for early detection of breast cancer in women who have no signs or indications of the illness. This kind of mammogram is called a selective or screening mammogram. This process is chosen according to the distinctiveness and preferences of women to find breast cancer when there are no obvious symptoms. Generally, a mammogram necessitates two radiographs or images of each breast. These images make it likely to identify possible tumors which cannot be felt through the skin or to find micro-calcifications that occasionally are a sign of the presence of breast cancer (What is a Mammogram, 2010).

Mammograms can also be utilized to find breast cancer after having discovered a lump or other indication or symptom of the cancerous tumor. This kind of mammogram is called a diagnostic mammogram. Some indications of breast cancer are pain, skin thickening, nipple discharge or a change in breast size or shape. Nevertheless, these indications can also be a sign of a benign abnormal cellular growth. A diagnostic mammogram may also be utilized to assess alterations found during a screening mammogram or to look at breast tissue when it is hard to get a screening mammogram because of particular conditions, for instance, the existence of breast implants (What is a Mammogram, 2010).

The age at which to start mammography for screening is very controversial. There have been eight key trials having to do with mammography screening. The change in breast cancer death has varied extensively amongst these studies. Differences in randomization methods, superiority of the mammograms, and period of follow-up and developing treatments for breast cancer throughout the trials have made it hard to come to a conclusion about mammographic screening. There have been several analyses of the effects of mammographic screening. Differences in these draw from the time they were done, the occurrence or nonexistence of follow-up data from individual trials, and the leaving out of certain trials in some analyses (Breast Disorders and Breast Cancer Screening, 2011).